References
- Abiramasundari G, Sumalatha K R, Sreepriya M (2012). Effects of Tinospora cordifolia (Menispermaceae) on the proliferation, osteogenic differentiation and mineralization of osteoblast model systems in vitro. J Ethnopharmacol, 141, 474-80.
- Agathanggelou A, Bieche I, Ahmed-Choudhury J, et al (2003). Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res, 63, 5344-51.
- Agathanggelou A, Cooper W N , Latif F (2005). Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res, 65, 3497-508. https://doi.org/10.1158/0008-5472.CAN-04-4088
- Ahmed-Choudhury J, Agathanggelou A, Fenton S L, et al (2005). Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter. Cancer Res, 65, 2690-7. https://doi.org/10.1158/0008-5472.CAN-04-3593
- Baksh S, Tommasi S, Fenton S, et al (2005). The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell, 18, 637-50. https://doi.org/10.1016/j.molcel.2005.05.010
- Blum R, Jacob-Hirsch J, Amariglio N, et al (2005). Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor- 1alpha, causing glycolysis shutdown and cell death. Cancer Res, 65, 999-1006.
- Bos J L (1989). ras oncogenes in human cancer: a review. Cancer Res, 49, 4682-9.
- Dallol A, Agathanggelou A, Fenton S L, et al (2004). RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res, 64, 4112-6. https://doi.org/10.1158/0008-5472.CAN-04-0267
- Dallol A, Agathanggelou A, Tommasi S, et al (2005). Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res, 65, 7653-9.
- Dammann R, Li C, Yoon J H, et al (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 25, 315-9. https://doi.org/10.1038/77083
- Downward J (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer, 3, 11-22. https://doi.org/10.1038/nrc969
- Gao B N, Xie X J, Huang C X, et al (2008). RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res, 68, 22-5. https://doi.org/10.1158/0008-5472.CAN-07-5183
- Goodsell D S (1999). The molecular perspective: the ras oncogene. Stem Cells, 17, 235-6. https://doi.org/10.1002/stem.170235
- Jadon R, Pembroke C A, Hanna C L, et al (2014). A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer. Clin Oncol (R Coll Radiol), 26, 185-96. https://doi.org/10.1016/j.clon.2013.11.031
- Liu W J, Tan X H, Guo B P, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a metaanalysis of published data. Asian Pac J Cancer Prev, 14, 3719-24. https://doi.org/10.7314/APJCP.2013.14.6.3719
- Malumbres M , Barbacid M (2003). RAS oncogenes: the first 30 years. Nat Rev Cancer, 3, 459-65. https://doi.org/10.1038/nrc1097
- Matallanas D, Romano D, Yee K, et al (2007). RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell, 27, 962-75. https://doi.org/10.1016/j.molcel.2007.08.008
- Parkin D M, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Rahbari R, Sheahan T, Modes V, et al (2009). A novel L1 retrotransposon marker for HeLa cell line identification. Biotechniques, 46, 277-84.
- Richter A M, Pfeifer G P , Dammann R H (2009). The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta, 1796, 114-28.
- Sherwood V, Recino A, Jeffries A, et al (2010). The N-terminal RASSF family: a new group of Ras-association-domaincontaining proteins, with emerging links to cancer formation. Biochem J, 425, 303-11. https://doi.org/10.1042/BJ20091318
- Srivastava A K, Singh P K, Srivastava K, et al (2013). Diagnostic role of survivin in urinary bladder cancer. Asian Pac J Cancer Prev, 14, 81-5. https://doi.org/10.7314/APJCP.2013.14.1.81
- van der Weyden L, Tachibana K K, Gonzalez M A, et al (2005). The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol, 25, 8356-67. https://doi.org/10.1128/MCB.25.18.8356-8367.2005
- Vos M D, Dallol A, Eckfeld K, et al (2006). The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem, 281, 4557-63. https://doi.org/10.1074/jbc.M512128200
- Walboomers J M, Jacobs M V, Manos M M, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
Cited by
- Aberrant Methylation of RASSF1A gene Contribute to the Risk of Renal Cell Carcinoma: a Meta-Analysis vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4665
- Association between RASSF1A Promoter Hypermethylation and Oncogenic HPV Infection Status in Invasive Cervical Cancer: a Meta-analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5749
- The tumor suppressive role of RASSF1A in osteosarcoma through the Wnt signaling pathway vol.37, pp.7, 2016, https://doi.org/10.1007/s13277-015-4660-z